Biomarkers in Locally Advanced Rectal Cancer: A Review

Shehara Mendis; Yat Hang To; Jeanne Tie

doi:10.1016/j.clcc.2021.11.002

Biomarkers in Locally Advanced Rectal Cancer: A Review

Clin Colorectal Cancer. 2022 Mar;21(1):36-44. doi: 10.1016/j.clcc.2021.11.002. Epub 2021 Nov 20.

Authors

Shehara Mendis¹, Yat Hang To², Jeanne Tie²

Affiliations

¹ Walter and Eliza Hall Institute, 1G Royal Parade, Parkville VIC 3052, Australia; 2. Western Health, Melbourne, VIC, Australia. Electronic address: [email protected].
² Walter and Eliza Hall Institute, 1G Royal Parade, Parkville VIC 3052, Australia; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

PMID: 34961731
DOI: 10.1016/j.clcc.2021.11.002

Abstract

Locally advanced rectal cancers (LARC) are the subject of a rapidly evolving treatment paradigm. The critical timepoints where management decisions are required during the care of the LARC patient are: prior to the institution of any treatment, post neoadjuvant therapy and post-surgery. This article reviews the clinical, imaging, blood-based, tissue-based, and molecular biomarkers that can assist clinicians at these timepoints in the patient's management, in prognosticating for their LARC patients or in predicting responses to therapy in the multi-modality neoadjuvant treatment era.

Keywords: Neoadjuvant chemoradiation; Prognosis; Rectal carcinoma; Survival; Treatment.

Publication types

Review

MeSH terms

Biomarkers
Chemoradiotherapy / methods
Humans
Neoadjuvant Therapy / methods
Neoplasms, Second Primary* / drug therapy
Rectal Neoplasms* / drug therapy
Rectal Neoplasms* / therapy
Rectum

Substances

Biomarkers